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Abstract
Background: Understanding the performance of prescribed medications in day-to-day practice is important
to minimize harm, maximize clinical benefits, and, eventually, better target the people who are most likely to
benefit, especially in hospice/palliative care where there may be limited time to optimize prescribing.
Metoclopramide, a benzamide prokinetic antiemetic, is widely used for a number of indications including
nausea, vomiting, hiccups, and reflux. It has recently had a new ‘‘black box’’ warning issued by the Food and
Drug Administration in relation to tardive dyskinesia to limit use to 12 weeks.
Methods: A consecutive cohort of patients from 12 participating centers in two countries who were having
metoclopramide initiated had data collected at three time points—baseline, 2 days (clinical benefit), and day 7
(clinical harm). Additionally, harms could be recorded at any time.
Results: Of the 53 people included in the cohort, 23 (43%) reported benefit at 48 hours, but only 18 (34%) of these
people were still using it one week after commencing it. For the other 5, the medication was ceased due to harms.
The most frequent harms were akathisia (n= 4), headache (n= 4), and abdominal pain (n = 4). Nine people (17%)
had no clinical benefit and experienced harms.
Conclusion: Overall, one in three people gained net clinical benefit at one week. Limiting effects include side-
effects that need to be sought actively in clinical care.
Introduction
The evidence base for prescribing in hospice/palliativecare can be improved. In response to this need, a multi-
national initiative has commenced to improve the data for net
clinical effect, and hence the evidence base on which to pred-
icate prescribing in hospice/palliative care.1 This work is an
extension of the phase III and IV studies that have been car-
ried out by the Australian Palliative Care Clinical Studies
Collaborative (PaCCSC).2
Rapid prospective reporting at agreed time points for as-
sessment with standardized measures of clinical harms and
benefits for frequently prescribed symptom control medica-
tions in hospice/palliative care can provide important infor-
mation. This information is unique to hospice/palliative care
and cannot be extrapolated from other patient populations.
Immediate and short-term net clinical effects can be system-
atically studied this way during day-to-day practice.
Using secureweb-based technology, de-identified and ‘‘un-
reidentifiable’’ data, and a small number of set fields focused
on single medications, a new pragmatic tool for pharmacov-
igilance has been created. This approach ensures that a con-
siderable amount of data can be rapidly brought together by
aggregating data from a large number of centers simulta-
neously with minimal work for each individual clinician.
The first medicine studied by the collaborative is metoclo-
pramide, a benzamide prokinetic antiemetic, widely used in
hospice/palliative care practice for a number of indications
including nausea, vomiting, hiccups, gastroesophageal reflux
disease, and gastroparesis (including that caused by opioids).
Although widely prescribed and affordable, the benefits and
harms of metoclopramide have not been well quantified in
hospice/palliative care patients. Given the new Food andDrug
Administration ‘‘black box’’ warning issued in 2009 limiting
recommended use to 12 weeks because of metoclopramide’s
propensity to cause irreversible tardive dyskinesia,3 it is timely
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to assess the net clinical effect of this medication in hospice/
palliative care practice. Key facts about metoclopramide are
shown in Table 1.
The aim of this study was to describe the clinical effect of
metoclopramide when prescribed routinely in a consecutive,
prospective cohort of hospice/palliative care patients.
Methods
The study methods have been described in detail previ-
ously.1 In summary, participating sites entered data pro forma
on consecutive patients started on this medication as part of
routine clinical care. Nonidentifying demographic and clini-
cal data were entered onto the 128-bit secure web portal. Pre-
specified clinical benefit and harm fields were defined by
an expert committee based on the available literature. The
National Cancer Institute’s Common Toxicity Criteria for
Adverse Events (NCI CTC) Likert scales for grading harms
were used.4 Clinical datawere recorded at three set time points:
baseline; after 48 hours (clinical benefit), and day 7 (short-term
harm). Additionally, harms could be recorded at any time.
Harms were attributed to metoclopramide if the criteria for
NCI CTC were > 0 at day 7. The domains within the Naranjo
Score that are applicable in this clinical setting were used
to help attribute the relationship between the medication
and any reported harms.5 Specifically, question 4 (drug read-
ministration), question 6 (same side effect when placebo ad-
ministrated), and question 8 (did harmful effects change with
dose?) were not included as they are not appropriate for hos-
pice/palliative care practice.
Descriptive data are presented.
Ethical waivers (by the relevant research ethics committees
that consider this an audit) or approval for low risk research
(where this program of work is considered research) were
granted for all participating sites.
Results
Data including demographic and baseline clinical data
(Table 2) were available on 53 people from 12 hospice/
palliative care sites in two countries who commenced treat-
ment with metoclopramide between October 2011 and Jan-
uary 2012. The majority of patients had cancer and
metoclopramide was prescribed for prevention of nausea or
Table 1. Key Facts: Metoclopramide
Mechanism of action Central Patient effects Anti-nausea
Physiological effects Acts on the chemoreceptor trigger zone and the
vomiting centre
Molecular effects Dopamine 2 antagonist at clinical doses
Peripheral Patient effects Less early satiety
Physiological effects Increased gastric and small bowel peristalsis, pyloric
sphincter relaxation
Molecular effects Dopamine 2 antagonist at clinical doses
Pharmacokinetics Bioavailability 70% oral
Clearance 80% metabolized, 20% renal, Metabolized by:
cytochromes P450 (CYP) 2D6 (major) and 3A
(minor)
Volume of distribution 3.5l/kg, crosses blood–brain barrier
Half life 5–6 hours
Dose modifications Reduce dose in severe renal impairment (one-quarter
normal dose) and severe liver failure (half normal
dose)
Frequently reported adverse
effects
Short-term use, or at any time Restlessness, fatigue, extra-pyramidal side effects
Long-term use Irreversible tardive dyskinesia
Consequences
Important examples of drug
interactions in hospice/palliative
care
Additive effect with other
dopamine antagonists
(haloperidol)
Increased likelihood of extrapyramidal effects
Inhibition of metabolism by
CYP2D6 inhibitors (fluoxetine)
Blocking of prokinetic effects
(anticholinergics such as
hyoscine butylbromide)
Reduced anti-nausea effect
Contraindications Reason: dopamine blockade Parkinson’s disease
Phaeochromocytoma
Prolactinoma
Monitoring Clinical Symptom burden
Biochemical n/a
Note: Bolded sections are serious or irreversible events.
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vomiting in the majority of patients. Patients were admin-
istered on average 32.9mg of metoclopramide /24 hours
(standard deviation 7.5; median 30mg; range 10–60) in in-
jectable or oral formulations.
By 48 hours, overall benefit was reported in 23 of 53 (43%)
patients (Table 3). One in 4 patients (15/53) had one point or
greater reduction in their relevant NCI CTC symptom score
and no side effects at one week. Another 15% (8/53) had
symptomatic benefit, but 5 of these patients had either ceased
their medication (2) or had changed to another antiemetic (3)
due to harmful effects. In total, at one week 18 of 53 (34%)
were still taking metoclopramide with a net clinical benefit.
A total of 17 patients experienced 24 harms (Table 4). The
most frequently encountered harms were akathisia (4 pa-
tients), headache (4 patients), and abdominal pain (4 patients).
Eleven patients had metoclopramide ceased with recorded
harms in this subgroup including akathisia (4), headache (4),
abdominal pain (4), tremor (1), dizziness (1), and ‘‘other’’ (7)
including sweats, drowsiness, fecal blood, and two patients
with bowel perforations. Five patients experienced toxicity at
Table 2. Baseline Clinical and Demographic Data: Rapid Reporting Metoclopramide
Pharmacovigilance Study in Hospice/Palliative Care
N (%) Median Range
Age 53 70 20–97
Gender (male) 20 (39)
Australian- modified Karnofsky
Performance Status score
53 (96) 50 20–90
Charlson Co-morbidity Index score 53 (100) 6 0–12
Body mass index 46 (83) 19 15–46
C reactive protein 19 (35) 33 6–300
Calculated creatinine clearance 24 (44) 62 17–150
National Cancer Institute Common
Toxicity Criteria grading for
most severe symptom
Indication for metoclopramidea Nausea 40 (76) 2 1–3
Vomiting 21 (40) 2 1–4
Hiccupsb 4 (8)
Refluxb 6 (12)
Primary life-limiting illness Cancer 50 (94)
End-stage renal disease 0
End-stage cardiac disease 1 (2)
End-stage respiratory disease 0
End-stage hepatic disease 2 (4)
AIDS 0
Neurodegenerative disease 0
Other 0
aThere may be more than one indication for the medication.
bOn one occasion for each was this the most severe symptom.
Table 3. Net Clinical Effects (Individual Patients)
Benefit/sa (1 point NCIc
reduction) Harm(s)b N (% of 53) Action following harm(s) N (% of 53)
Yes (23) No 15 (28) Ceased (2); other med (1) 3 (6)
Yes 8 (15) Cessationd 5 (9)
Change to other medicationd 4 (8)
Dose reductiond 0
No change in medicationd 3 (6)
Otherd 1 (2)
No (30) No 21 (40) Extra PRN dose(1) 1 (2)
Yes 9 (17) Cessationd 6 (11)
Change to other medicationd 3 (6)
Dose reductiond 0
No change in medicationd 2 (4)
Otherd 1 (2)
aReported at 2 days.
bReported at 7 days.
cNational Cancer Institute’s Common Toxicity Criteria.
dMore than one response is allowed.
PRN, pro re nata.
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NCI CTC grade III or greater. Despite this, 3 of the 5 experi-
enced clinical reduction in nausea (one patient with akathisia,
one with abdominal pain, and one with drowsiness); 2 of the
5 did not experience clinical benefit (both had headaches).
Discussion
This study details the actual performance of metoclopra-
mide in daily hospice/palliative care practice across a range
of clinical settings by codifying clinical benefits and harms.
Although no new harms were identified, 32% of people ex-
perienced harms. Given the wide use of metoclopramide
in hospice/palliative care, this study suggests that careful
attention to eliciting symptoms including akathisia (restless-
ness and motor agitation) and tremor are warranted, both of
which may be missed clinically if not specifically sought, or
attributed to other causes. Rates are likely to be higher when
metoclopramide is prescribed with other dopamine antago-
nists (e.g., haloperidol, promethazine) that can also induce
these side effects in hospice/palliative care practice.6,7
The overall positive responsewith acceptable harms of 34%
is low given the prevalent use of metoclopramide, although a
census point later than 2 daysmay increase positive responses
further. This may in part be due to an inability to measure
the benefit of prophylactic use. If there is no clinical benefit
at 48 hours, it is not clear that there will predictably be an
increased number of patients who derive benefit subsequently.
Conversely, harms such as akathisia may have an onset much
later than one week of treatment with metoclopramide.
The current data reflect the two most recent systematic
reviews that reflect the population with advanced life-
limiting illnesses where symptoms were not related to che-
motherapy or radiotherapy.8,9 Davis’ review concluded that
there was ‘‘moderate evidence’’ for the use of metoclopra-
mide as first-line therapy for nausea, and this was the best
level of evidence available for any antiemetic with many
other widely used medications having no randomized con-
trolled data to support their use.8 There was no evidence
metoclopramide has an effect on opioid-induced emesis.8
Glare and colleagues note that randomized controlled trials
(RCTs) had much lower response rates to single arm, open
label studies, and the findings of the current pharmacov-
igilance study demonstrate outcomes comparable with the
RCTs for nausea (response rates 23% to 36%) and emesis
(18% to 52%).9 It is expected that a prospective pharmacov-
igilance study would have net benefits at lower rates than
a selected population in a randomized controlled trial or a
retrospective case series.
Limitations
This study only addresses immediate and short-term
harms. Longer-term harms or rare but catastrophic harmswill
need to be studied with either longer periods of surveillance
or by other mechanisms such as integrating prescribing
datasets linked to comprehensive electronic medical records
or ad hoc clinician reporting. The latter is limited by recogni-
tion of only the most florid examples. The effects of pro re nata
(PRN) prescribing is not covered nor is there a way to simply
measure drug interactions.
The modified Naranjo score including only five of the
questions of relevance to practice was collected as an aggre-
gate number. This made its interpretation difficult, and the
individual scoring for each question is what is being collected
in subsequent studies.
It is a relatively small sample size in this, the first of these
studies.
Ensuring consistent interpretation for the measurement of
outcomes between sites is crucial to the quality of the data. For
subsequent studies, educational material will be developed
for each outcome in both clinical benefit and clinical harm.
Generalizability
The sample was drawn from a wide range of practices in-
cluding direct care and consultative inpatient services, com-
munity care, and from outpatient clinics. The age distribution
and diagnoses represented reflect many hospice/palliative
care practices around the world.
Implications for clinical practice
These data reiterate the need to understand the clinical
endpoints sought when initiating a new medication,10 and
the relatively low likelihood of this single pharmacological
intervention totally controlling nausea without any side
effects.
Table 4. Harms at Any Time in the 2 Weeks after Initiating Metoclopramide in Hospice/Palliative Care
Response n = 40 people
Severityb Cessation
Other medication
introduced
Dose
reduction
No change
in medication Other
N (%) harmsa median (range) n = 11 n = 7 n = 0 n = 12 n = 2
Rigidity 0
Akathisia 4 (10) 2.5 (1–4) 3 3 2
Gait change 0
Tremor 2 (5) 1 (1) 1 1 1
Headache 4 (10) 2 (1–4) 2 1 2
Dizziness 1 (3) 2 (2) 1 1
Abdominal pain 4 (10) 2 (1–2) 4
Vomiting 2 (5) 2 (1–2) 2
Other 7 (18) 3 (1–3) 3 1 1 2
aParticipants can have more than one harm but can also have more than one response.
bNational Cancer Institute’s Common Toxicity Criteria (NCI CTC).
Other: Drowsiness (2), diarrhea, bowel perforation (2), sweats, blood in feces.
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Future directions
Two people having bowel perforations seems high in this
patient population. Rare but catastrophic events will need a
separate reporting mechanism that is under consideration,
which would include formal assessment of causality.
A different medication and one of its indications will be
studied approximately every 3 months. We hope that more
centers will join this initiative given the very limited impost
on clinicians (10 minutes per participant in total), with the
ability to accrue and collate relatively large amounts of data
rapidly. (Contact david.currow@flinders.edu.au if your unit
is interested in joining).
In the next medication, harm will be measured at baseline
in addition to the data point specifically for harms to improve
the ability to attribute the harms reported during the obser-
vation period to the index medication. Reasons for data not
being available will also be systematically captured.
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